Evidence map›Paper›PMID 41572330›Full record

ArticleExperimental hematology & oncology2026

Resilience of human tolerogenic dendritic cells to physiological oxygen supports clinical application: functional stability amidst glycolytic and differentiation shifts.

Antonia Peter, Tamara Traitteur, Sara Calitz, Morgane Vermeulen, Mats Van Delen, Amber Dams, Stefanie Peeters, Carole Faghel, Hans De Reu, Waleed F A Marei and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Antonia PeterLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium. antonia.peter@uantwerpen.be.
Tamara TraitteurLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Sara CalitzLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Morgane VermeulenLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Mats Van DelenLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Amber DamsLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Stefanie PeetersLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Carole FaghelLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Hans De ReuLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Waleed F A MareiGamete Research Centre, Laboratory of Veterinary Physiology and Biochemistry, Department of Veterinary Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Zwi N BernemanLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.
Nathalie CoolsLaboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610, Antwerp, Belgium.

Funding

BOF infrastructure grant from the University of Antwerp 543600001FWO Hercules infrastructure fund I010524NHORIZON EUROPE Marie Sklodowska-Curie Actions 860003Research Foundation-Flanders (FWO-Vlaanderen) T002523NSpecial Research Fund (BOF) of the University of Antwerp DOCPRO1, PS ID 49061Special Research Fund (BOF) of the University of Antwerp DOCPRO4, PS ID 5114the Industrial Research Fund (IOF) of the University of Antwerp SEP, PS ID 53192Universitair Ziekenhuis Antwerpen 21HMT17
6 · The paper itself

Abstract

Tolerogenic dendritic cells (tolDCs) hold promise for treating autoimmune diseases, potentially restoring antigen-specific immune tolerance without systemic immunosuppression. However, their behavior in vivo remains incompletely understood, particularly in response to microenvironmental factors such as oxygen (O

Indexed as

Dendritic cell-based vaccineImmunometabolismOxygenToleranceTolerogenic dendritic cells

Identifiers

PMID41572330
PMCPMC12829039

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.